Home › Glioma › Pennsylvania › Philadelphia
Studi clinici su Glioma a Philadelphia, PA
16 studi su Glioma cercano partecipanti presso sedi a Philadelphia e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
In reclutamentoFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
- Saint Christopher's Hospital for Children, Philadelphia
- Alfred I duPont Hospital for Children, Wilmington · a 25 mi di distanza
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
In reclutamentoFase 2
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
In reclutamentoFase 1/2
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
In reclutamentoFase 1 iniziale
- The Children s Hospital of Philadelphia, Philadelphia
Targeted Pediatric High-Grade Glioma Therapy
In reclutamentoStudio osservazionale
- Children's Hospital of Philadelphia, Philadelphia
Study of Olutasidenib and Temozolomide in HGG
In reclutamentoFase 2
- Children's Hospital of Philadelphia, Philadelphia
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
In reclutamentoFase 3
- Thomas Jefferson University Hospital, Philadelphia
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
In reclutamentoFase 2
- Children's Hospital of Philadelphia, Philadelphia
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
In reclutamentoFase 1
- Children's Hospital of Philadelphia, Philadelphia
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
In reclutamentoFase 2
- Thomas Jefferson University, Philadelphia
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
In reclutamentoFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
In reclutamentoFase 1 inizialeVolontari sani benvenuti
- Children's Hospital of Philadelphia, Philadelphia
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
In reclutamentoFase 2
- Children's Hospital of Philadelphia, Philadelphia
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
In reclutamentoFase 1 iniziale
- Children's Hospital of Philadelphia, Philadelphia
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
In reclutamentoFase 2
- University of Pennsylvania, Philadelphia
18F-Fluciclovine PET-MRI in High-grade Glioma
In reclutamentoFase 1 iniziale
- Children's Hospital of Philadelphia, Philadelphia
Studi su Glioma in altre città
- New York City, NY25 studi
- Houston, TX23 studi
- Boston, MA20 studi
- Washington, DC19 studi
- Columbus, OH15 studi
- Miami, FL15 studi
- San Francisco, CA14 studi
- Chicago, IL13 studi
- Durham, NC12 studi
- Seattle, WA11 studi
- St. Louis, MO10 studi
- Aurora, CO10 studi
Altri studi a Philadelphia
- Cancro (tutti i tipi)59 studi
- Cancro al seno56 studi
- Cancro del polmone non a piccole cellule51 studi
- Cancro metastatico46 studi
- Cancro alla prostata44 studi
- Cancro colorettale44 studi
- Cancro ovarico44 studi
- Cancro ai polmoni36 studi
- Leucemia mieloide acuta34 studi
- Insufficienza cardiaca31 studi
- Cancro dell'endometrio28 studi
- Depressione26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.